Research suggests that medications are not taken as prescribed half of the time, which could lead to reduced efficacy of the treatment and increased risk of negative health outcomes. In addition, nearly half of all drug launches underperform as compared to prelaunch expectations. These statistics highlight the drawbacks of the traditional development approach, which is largely driven by cost and timelines. The incorporation of patient-focused drug design principles early in the development cycle is critical to developing safe and effective treatments that address the specific needs of target patient populations in-terms of appropriateness, preference and usability. Ultimately, patient preference and differentiation from competitors are two factors that can lead to market acceptability.
Join this webinar to discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes.